PCOS: metformin associated with improved endothelial function

  • Heidari B & al.
  • Mayo Clin Proc
  • 1 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Metformin is associated with improved endothelial function in patients with polycystic ovary syndrome (PCOS), according to a small trial.

Why this matters

  • PCOS has been linked to increased risk for cardiometabolic syndrome.

Key results

  • Metformin was associated with improved endothelial function in patients with abnormal baseline endothelial function (P<.001>
  • Metformin was not associated with altered endothelial function in patients with normal baseline endothelial function (P=.11).
  • Baseline endothelial dysfunction was a significant predictor of change in endothelial function in analysis adjusted for homeostasis model assessment of insulin resistance (P=.002).

Study design

  • 42 women with PCOS were randomly assigned to 1500 mg/day of metformin (N=29) or no treatment (N=13) for 3 months.
  • Funding: St. Jude Medical Foundation; NIH; National Center for Advancing Translational Sciences.

Limitations

  • Small patient sample size.
  • No long-term follow-up.
  • No placebo-controlled group.